Supplemental material,"Ixekizumab’s early effectiveness is altered by metabolic syndrome in patients with psoriasis: a 12-week, single-center, retrospective study"

Published: 15 November 2021| Version 1 | DOI: 10.17632/vdvm5ncnxt.1
Kun Hu


Supplemental Table 2. The comparison of the rate of PASI 75, PASI 90 and PASI 100 in different baseline metabolic syndrome status by GEE models.GEE, generalized estimating equation; MetS, metabolic syndrome; PASI, Psoriasis Area Severity Index; OR, odds ratio; CI, confidence interval. There were significant differences in PASI improvement between patients with versus without metabolic syndrome(P<0.05). Supplemental Table 3. Results of multivariable logistic regression analyses investigating risk factors of PASI 75/90/100 at week 4 and PASI 100 at week 8.PASI, Psoriasis Area Severity; HDL, high density lipoprotein; BP, blood pressure; *P<0.05 P values are significant; CI, confidence interval; OR, odds ratio.This table presents the odds ratios and corresponding 95% confidence intervals (CIs) investigating the associations between baseline risk factors of metabolic syndrome and the attainment of ≥ 75%, 90% and 100% improvement in Psoriasis Area and Severity Index (PASI) at week 4 and 100% improvement in PASI at week 8. Supplemental Fig 1A. Proportions of 89 patients who achieved Psoriasis Area and Severity Index (PASI) 75, 90, and 100 through week 12. All patients who continuously received the shortened-interval regimen of ixekizumab. PASI 75, PASI 90, and PASI 100 response mean patients achieving 50%, 90% and 100% PASI reduction, respectively, or greater reduction from baseline PASI. Supplemental Fig 2. Multivariable adjusted analysis of variables associated with PASI 75/90/100 response.CI, confidence interval; OR, odds ratio; PASI, Psoriasis Area Severity Index. Variables included in model were waist circumference, HDL level, triglycerides level, fasting glucose, and blood pressure at baseline; *P<0.05 P values are significant.



Health Sciences